HENGRUI THERAPEUTICS, INC.
  • Home
  • Who We Are
  • R&D
  • News
    • News and Buzz
    • Scientific and Medical Releases
  • Partners
  • Careers
  • Contact
  • News and Buzz

TEAMWORK...MATTERS

OUR PARTNERS
​

We are actively developing alliances with companies, clinicians, patient organizations and academic scientists. Collaborations are core to expand and grow our capabilities, so that we can provide better healthcare for patients.

​For more information or inquiries on collaborations and partnerships, please email info@hengruitx.com

CLINICAL TRIAL PARTNERS

Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture

ACADEMIC RESEARCH COLLABORATORS

Novel Immuno-Oncology Targets Identification
​

Immuno-Oncology Antibody  Research & Drug Candidate Generation
Immuno-Oncology Antibody Drug Candidate Generation and Combination Studies
Picture
Picture
Picture

GLOBAL DEVELOPMENT PARTNERSHIPS

Picture
In January 2018, TG Therapeutics and Jiangsu Hengrui Medicine announced a global license agreement for development and commercialization of novel BTK Inhibitor Program for the treatment of hematologic malignancies.
learn more
Picture
In January 2018, Arcutis and Jiangsu Hengrui Medicine announced a development and commercialization partnership for novel immune-mediated dermatology therapy using a potentially best-in-class JAK inhibitor discovered by Hengrui.
learn more

HOME


​

WHO WE ARE
Our Team

R&D
HTI Pipeline Overview
R&D Sites​
​

NEWS
News and Buzz
Scientific and Medical Releases

PARTNERS
Clinical Trial Partners
Academic Partners
Corporate Alliances

CAREERS
Job Opportunities

CONTACT
506 Carnegie Center, ​Suite 102
Princeton, NJ 08540
609.423.2155

​info@hengruitx.com

​

Picture
Copyright © 2018
  • Home
  • Who We Are
  • R&D
  • News
    • News and Buzz
    • Scientific and Medical Releases
  • Partners
  • Careers
  • Contact
  • News and Buzz